Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Published On 2021-12-02 05:12 GMT | Update On 2021-12-15 06:31 GMT

Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to "experience a clinical benefit" over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights.

The benefits of empagliflozin in this very early acute setting, included better survival, fewer hospitalizations, and greater improvements quality of life (QoL)—all of which made up the primary composite endpoint in this study

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Similar News

Study Provides Insights on NSAIDs Double Internal Bleeding Risk in Patients on Anticoagulants

Can Heart Shape Predict Risk for Cardiovascular Diseases? Study Sheds Light

Sitting more Than 10 Hours May Put Heart Health at Risk: Study Suggests

Can Heart Medicine Lead to Depression? Study Sheds Light

Rare Disease Show Episode 19: Decoding Pulmonary Arterial Hypertension with Dr Brajesh Kumar Mishra

Journal Club- Association between blood pressure, body mass index, and age: A data analytic approach

Climb Stairs to Control Blood Pressure: Study Finds

Can Work Place Stress Be a Silent Threat to Your Heart Health? Study Sheds Light